Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-Galmydar Dosimetry in Healthy Volunteers
NCT05280782Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Ga-68 Galmydar in coronary artery disease (CAD), sponsored by Washington University School of Medicine. Primary endpoints: Organ Dosimetry at 6 hours, Biodistribution at 6 hours and 1 more. Started Jan 2022; status: completed.
02
Drugs
Ga-68 Galmydar
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05280782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05280782.